目的 探討肝蘇膠囊聯(lián)合黃芩苷膠囊治療慢性乙型病毒性肝炎的臨床療效。方法 選取2013年6月-2016年1月鄂東醫(yī)療集團(tuán)市中醫(yī)醫(yī)院診治的慢性乙型病毒性肝炎患者88例，隨機(jī)分為對(duì)照組和治療組，每組各44例。對(duì)照組餐后30 min口服黃芩苷膠囊，0.5 g/次，3次/d。治療組在對(duì)照組基礎(chǔ)上餐后30 min口服肝蘇膠囊，1.2 g/次，3次/d。兩組患者均治療6個(gè)月。觀察兩組的臨床療效，比較兩組的丙氨酸氨基轉(zhuǎn)移酶（ALT）、天冬氨酸氨基轉(zhuǎn)移酶（AST）、總膽紅素（TBIL）、乙肝病毒的脫氧核糖核酸（HBV-DNA）、透明質(zhì)酸、III型前膠原、IV型膠原和層粘連蛋白的情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為73.64%、86.36%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組ALT、AST、TBIL和HBV-DNA水平均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組透明質(zhì)酸、III型前膠原、IV型膠原和層粘連蛋白均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的下降程度明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 肝蘇膠囊聯(lián)合黃芩苷膠囊具有較好的臨床療效，能降低患者的ALT、AST、TBiL和HBV-DNA水平，減輕肝臟纖維化的程度，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Sugan Capsules combined with Baicalin Capsules in treatment of chronic hepatitis B. Methods Patients (88 cases) with chronic hepatitis B in Edong Healthcare City Hospital of Traditional Chinese Medicine from June 2013 to January 2016 were randomly divided into control and treatment groups, and each group had 44 cases. Patients in the control group were po administered with Baicalin Capsules after meals 30 min, 0.5 g/time, three times daily. Patients in the treatment group were po administered with Sugan Capsules on the basis of the control group after meals 30 min, 1.2 g/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and ALT, AST, TBIL, HBV-DNA, hyaluronic acid, type III procollagen, type IV collagen, and laminin in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.64% and 86.36%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of ALT, AST, TBIL, and HBV-DNA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, hyaluronic acid, type III procollagen, type IV collagen, and laminin in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Sugan Capsules combined with Baicalin Capsules has clinical curative effect in treatment of chronic hepatitis B, can decrease the levels of ALT, AST, TBIL, and HBV-DNA, and reduce the degree of liver fibrosis, which has a certain clinical application value.